• Stryker recently reported first-quarter 2026 results showing sales of US$6,020 million and net income of US$745 million, alongside a quarterly dividend of US$0.88 per share payable on July 31, 2026, to shareholders of record on June 30, 2026, representing a 4.8% increase versus the prior year.
• Together with directors and executives receiving new restricted stock unit awards that tie their compensation to future company performance, these earnings and dividend decisions highlight how Stryker’s leadership is closely aligning pay, capital returns, and operating results.
• We’ll now examine how Stryker’s stronger quarterly earnings and dividend increase may influence the existing investment narrative built around growth and margins.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Stryker Investment Narrative Recap

To own Stryker, you generally need to believe in steady procedure demand, continued innovation in devices and robotics, and management’s ability to protect margins despite regulatory, supply chain, and pricing pressures. The latest US$6,020 million Q1 2026 sales, higher net income, and a maintained US$0.88 dividend support the current narrative but do not materially change the near term focus on supply chain stability as a key catalyst or regulatory and pricing pressures as central risks.

The most relevant update here is the US$0.88 per share dividend, up 4.8% versus a year ago and unchanged from last quarter. For many shareholders, this sits alongside earnings progress as a reminder that capital returns currently coexist with ongoing risks around tariffs, EU MDR approvals, and integration costs, which could all influence how sustainable that balance between growth and margins proves to be.

Yet, investors should also be aware that prolonged EU MDR approval timelines could still...

Stryker’s narrative projects $32.0 billion revenue and $6.1 billion earnings by 2029. This requires 8.4% yearly revenue growth and an earnings increase of about $2.9 billion from $3.2 billion today.

Uncover how Stryker's forecasts yield a $419.11 fair value, a 42% upside to its current price.

Exploring Other Perspectives

Six members of the Simply Wall St Community now place Stryker’s fair value between US$340.49 and US$419.11, underlining how far opinions can stretch. You should weigh those views against ongoing concerns about regulatory delays in Europe that could affect product launches and revenue momentum over time.

Explore 6 other fair value estimates on Stryker - why the stock might be worth just $340.49!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Stryker research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Stryker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stryker's overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.